Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MBI vs PMI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MBI Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)
MBI Overall Winner
6-Pillar Tally: MBI 5 – 1 PMI
Matrix Metrics: MBI 5 – 4 PMI
As of Nov 19, 2026, MBIA Inc. (MBI) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBI carries a Unified Composite Score of 44.0/100 (HOLD) at $4.37 (87.0x Forward P/E, 22.8% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).
- Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. MBI 44.0/100 HOLD), MBI captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.8% vs. -248.1% operating margin) and revenue trajectory (+46.7% vs. +38.6% YoY).
- Technical & Structure Timing Caution: MBI is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 40.8); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MBI vs PMI
MBI
Head-to-Head Winner
MBIA Inc.
$4.37
-2.24% 1D
Market Cap
$228.1M
TTM Revenue
$101M
Forward P/E
87.0x
Beta / 30D Vol
0.25β · 31% Vol
Unified Composite Score
44.0
HOLD
Tech 46.0
Fund 52.0
Flow 58.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
PMI
Picard Medical, Inc.
$6.30
-2.17% 1D
Market Cap
$17.1M
TTM Revenue
$6.3M
Forward P/E
N/M
Beta / 30D Vol
54.06β · 134% Vol
Unified Composite Score
48.4
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (MBI 5 – 1 PMI)
1. Valuation Multiples
MBI
Forward P/E
87.0x
N/M
Trailing P/E
87.0x
2.9x
PEG Ratio
1.71x
N/M
EV / Revenue
2.3x
3.2x
2. Growth & Scale
MBI
Revenue Growth (YoY)
+46.7%
+38.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$101M
$6.3M
Market Cap
$228.1M
$17.1M
3. Profitability & Quality
MBI
Gross Margin
88.1%
18.6%
Operating Margin
22.8%
-248.1%
Net Profit Margin
-159.4%
0.0%
Return on Equity (ROE)
0.0%
0.0%
4. Balance Sheet & Cash Flow
MBI
Cash Generation (TTM)
-$120M
-$17M
Cash Flow Margin
-118.8%
N/A
Net Cash / Leverage
0.0% ROE
$3.2M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PMI
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
46.5% (10th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Distribution
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
MBI
OpEx & R&D Intensity
65.3% of Rev ($66M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Insurance - Specialty Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MBI (5) vs PMI (4)| Institutional Metric | MBI | PMI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $228.1M | $17.1M | MBI | |
| Trailing P/E Ratio | 87.0x | 2.9x | PMI | |
| Forward P/E Ratio | 87.0x | N/M | MBI | |
| Revenue Growth (YoY) | +46.7% | +38.6% | MBI | |
| Operating Margin (TTM) | 22.8% | -248.1% | MBI | |
| Net Profit Margin | -159.4% | 0.0% | PMI | |
| Return on Equity (ROE) | 0.0% | 0.0% | Tie | |
| 52-Week Range Position | 5% ($4–$8) | 34% ($0–$18) | PMI | |
| Beta / 30D Volatility | 0.25β · 31% Vol | 54.06β · 134% Vol | MBI | |
| Unified Institutional Score | 44.0 / 100 (HOLD) | 48.4 / 100 (HOLD) | PMI | |
| Trailing 12M Revenue (USD) | $101M | $6.3M | Scale | |
| Gross Profit Margin (TTM) | 88.1% | 18.6% | Quality | |
| PEG Ratio & EV / Revenue | 1.71x PEG · 2.3x EV/Rev | N/M PEG · 3.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$120M (0.0% ROE) | -$17M ($3.2M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MBI +33.67 pp
3M Horizon
PMI +107.08 pp
6M Horizon
PMI +3468.62 pp
1Y Horizon
PMI +190.83 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MBI Revenue | PMI Revenue | MBI Op. Margin | PMI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $160M | N/A | -182.7% | N/A | MBI |
| FY2019 | $280M | N/A | -128.2% | N/A | MBI |
| FY2020 | $280M | N/A | -205.0% | N/A | MBI |
| FY2021 | $190M | N/A | -235.4% | N/A | MBI |
| FY2022 | $150M | N/A | -126.6% | N/A | MBI |
| FY2023 | $10M | N/A | 6814.3% | N/A | MBI |
| FY2024 | $40M | $0M | 1035.7% | -312.3% | MBI |
| FY2025 | $80M | $0M | -221.2% | -268.4% | MBI |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MBI
BREAKDOWN
Current IV
46.5%
IV Percentile
10th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MBI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PMI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MBI Moat Profile
Scale & Operating Efficiency Moat
Insurance - Specialty Operator
OpEx & R&D Reinvestment
65.3% of Rev ($66M)
90D Engineering Disclosures
0 Published
PMI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MBI vs PMI Key Questions & Quantitative Answers
As of Nov 19, 2026, MBIA Inc. (MBI) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBI carries a Unified Composite Score of 44.0/100 (HOLD) at $4.37 (87.0x Forward P/E, 22.8% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. MBI 44.0/100 HOLD), MBI captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.8% vs. -248.1% operating margin) and revenue trajectory (+46.7% vs. +38.6% YoY). Technical & Structure Timing Caution: MBI is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 40.8); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MBI leads the Growth & Scale pillar: MBI posts +46.7% YoY revenue growth and +0.0% YoY earnings growth on $101M TTM revenue (88.1% gross margin, 22.8% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MBI cumulative revenue shifted -50.0% while PMI shifted N/A. In operating R&D and SG&A reinvestment, MBI deploys 65.3% of Rev ($66M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.
MBI screens cheaper on headline valuation multiples. MBI trades at 87.0x Forward P/E, 87.0x Trailing P/E, 1.71x PEG, and 2.3x EV/Revenue (-118.8% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBI (0.0% ROE) versus PMI (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MBI carries 46.5% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.25β · 31% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PMI vs MBI · Reverse Pair
MBI vs MTG
· Sector Peer
MBI vs RDN
· Sector Peer
MBI vs AGO
· Sector Peer
PMI vs RDN
· Sector Peer
PMI vs MTG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem